EP4720281A2 - Inhibitoren der expression und/oder funktion - Google Patents
Inhibitoren der expression und/oder funktionInfo
- Publication number
- EP4720281A2 EP4720281A2 EP24727438.4A EP24727438A EP4720281A2 EP 4720281 A2 EP4720281 A2 EP 4720281A2 EP 24727438 A EP24727438 A EP 24727438A EP 4720281 A2 EP4720281 A2 EP 4720281A2
- Authority
- EP
- European Patent Office
- Prior art keywords
- strand
- seq
- inhibitor
- nucleosides
- nucleic acid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
- C12N15/1138—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against receptors or cell surface proteins
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/31—Chemical structure of the backbone
- C12N2310/315—Phosphorothioates
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/32—Chemical structure of the sugar
- C12N2310/321—2'-O-R Modification
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/32—Chemical structure of the sugar
- C12N2310/322—2'-R Modification
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/33—Chemical structure of the base
- C12N2310/332—Abasic residue
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/35—Nature of the modification
- C12N2310/351—Conjugate
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/35—Nature of the modification
- C12N2310/352—Nature of the modification linked to the nucleic acid via a carbon atom
- C12N2310/3521—Methyl
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/35—Nature of the modification
- C12N2310/353—Nature of the modification linked to the nucleic acid via an atom other than carbon
- C12N2310/3533—Halogen
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Biomedical Technology (AREA)
- Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Molecular Biology (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Microbiology (AREA)
- Plant Pathology (AREA)
- Biophysics (AREA)
- Physics & Mathematics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Animal Behavior & Ethology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Heart & Thoracic Surgery (AREA)
- Urology & Nephrology (AREA)
- Cardiology (AREA)
- Vascular Medicine (AREA)
- Epidemiology (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP23175699 | 2023-05-26 | ||
| US202463571886P | 2024-03-29 | 2024-03-29 | |
| PCT/EP2024/064367 WO2024245930A2 (en) | 2023-05-26 | 2024-05-24 | Inhibitors of expression and/or function |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| EP4720281A2 true EP4720281A2 (de) | 2026-04-08 |
Family
ID=91186754
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| EP24727438.4A Pending EP4720281A2 (de) | 2023-05-26 | 2024-05-24 | Inhibitoren der expression und/oder funktion |
Country Status (8)
| Country | Link |
|---|---|
| EP (1) | EP4720281A2 (de) |
| JP (1) | JP2026520457A (de) |
| KR (1) | KR20260029506A (de) |
| CN (1) | CN122206797A (de) |
| AU (1) | AU2024279697A1 (de) |
| IL (1) | IL324890A (de) |
| MX (1) | MX2025014063A (de) |
| WO (1) | WO2024245930A2 (de) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2025202455A2 (en) * | 2024-03-29 | 2025-10-02 | E-Therapeutics Plc | Inhibitors of expression and/or function |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2003233634A1 (en) * | 2002-05-20 | 2003-12-12 | Pharmacia Corporation | Antisense modulation of glucocorticoid receptor expression |
| EP2305813A3 (de) * | 2002-11-14 | 2012-03-28 | Dharmacon, Inc. | Funktionale und hyperfunktionale siRNA |
| WO2006006948A2 (en) * | 2002-11-14 | 2006-01-19 | Dharmacon, Inc. | METHODS AND COMPOSITIONS FOR SELECTING siRNA OF IMPROVED FUNCTIONALITY |
| WO2006002022A2 (en) * | 2004-06-15 | 2006-01-05 | Immusol Incorporated | Compositions and methods useful for the treatment of hyperglycemia |
| US11560563B2 (en) | 2018-04-05 | 2023-01-24 | Silence Therapeutics Gmbh | SiRNAs with vinylphosphonate at the 5′ end of the antisense strand |
| WO2022162161A1 (en) * | 2021-01-30 | 2022-08-04 | E-Therapeutics Plc | Conjugated oligonucleotide compounds, methods of making and uses thereof |
-
2024
- 2024-05-24 WO PCT/EP2024/064367 patent/WO2024245930A2/en not_active Ceased
- 2024-05-24 CN CN202480048991.2A patent/CN122206797A/zh active Pending
- 2024-05-24 EP EP24727438.4A patent/EP4720281A2/de active Pending
- 2024-05-24 AU AU2024279697A patent/AU2024279697A1/en active Pending
- 2024-05-24 IL IL324890A patent/IL324890A/en unknown
- 2024-05-24 JP JP2025569000A patent/JP2026520457A/ja active Pending
- 2024-05-24 KR KR1020257043077A patent/KR20260029506A/ko active Pending
-
2025
- 2025-11-24 MX MX2025014063A patent/MX2025014063A/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| AU2024279697A1 (en) | 2026-01-08 |
| MX2025014063A (es) | 2026-03-02 |
| IL324890A (en) | 2026-01-01 |
| CN122206797A (zh) | 2026-06-12 |
| WO2024245930A3 (en) | 2025-03-06 |
| WO2024245930A2 (en) | 2024-12-05 |
| KR20260029506A (ko) | 2026-03-04 |
| JP2026520457A (ja) | 2026-06-23 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20250368992A1 (en) | Nucleic acid compounds | |
| CA3249744A1 (en) | EXPRESSION AND/OR FUNCTION INHIBITORS | |
| WO2024165571A2 (en) | Inhibitors of expression and/or function | |
| KR20250043473A (ko) | 핵산 화합물 | |
| US20250320494A1 (en) | Inhibitors of expression and/or function | |
| WO2024023254A1 (en) | Nucleic acid compounds | |
| WO2024023267A2 (en) | Nucleic acid compounds | |
| WO2024245930A2 (en) | Inhibitors of expression and/or function | |
| AU2023313029A1 (en) | Double stranded nucleic acid compounds inhibiting zpi | |
| EP4707391A1 (de) | Nukleinsäure-verbindungen | |
| EP4652283A1 (de) | Nukleinsäureverbindungen zur zpi-hemmung | |
| US20250388897A1 (en) | Nucleic acid compounds | |
| WO2025125576A2 (en) | Inhibitors of expression and/or function | |
| WO2025021989A1 (en) | Inhibitors of expression and/or function | |
| CA3258247A1 (en) | NUCLEIC ACID COMPOUNDS | |
| WO2025202455A2 (en) | Inhibitors of expression and/or function | |
| EP4662315A2 (de) | Inhibitoren der expression und/oder funktion | |
| OA21722A (en) | Compositions and methods for inhibiting expression of Prekallikrein (PKK) protein. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: UNKNOWN |
|
| STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE |
|
| PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
| STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE |
|
| 17P | Request for examination filed |
Effective date: 20251203 |
|
| AK | Designated contracting states |
Kind code of ref document: A2 Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC ME MK MT NL NO PL PT RO RS SE SI SK SM TR |